SCHEMBL26439338

SCHEMBL26439338

CC(C)(C)OC(=O)N1C[C@H](C(=O)O)OC[C@@H]1Cc1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.41
▸ RORC P51449 2/20 0.40
▸ NR1H2 P55055 3/20 0.39
▸ NR1H3 Q13133 3/20 0.39
▸ ESRRB O95718 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ESRRA P11474 1/20 0.36
▸ ESRRG P62508 1/20 0.36
▸ KLK7 P49862 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ MCL1 Q07820 2/20 0.35
▸ FPR3 P25089 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ KCNK3 O14649 1/20 0.34
▸ KCNK9 Q9NPC2 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ CETP P11597 1/20 0.34
▸ SRC P12931 2/20 0.33
▸ ABCB1 P08183 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26439343 0.89 KMT2A (0.40) KMT2ARORCNR1H2NR1H3KLK7
SCHEMBL18577422 0.89 NR1H2 (0.39) KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL18607758 0.89 NR1H2 (0.39) KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL18607649 0.89 NR1H2 (0.39) KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL18589427 0.89 NR1H2 (0.39) KMT2ANR1H2NR1H3SMN1; SMN2
SCHEMBL26439349 0.85 NR1H2 (0.39) KMT2ARORCNR1H2NR1H3KLK7
SCHEMBL22903606 0.85 NR1H2 (0.38) KMT2ARORCNR1H2NR1H3FPR3
SCHEMBL22903811 0.85 NR1H2 (0.38) KMT2ARORCNR1H2NR1H3FPR3
SCHEMBL22903580 0.84 NR1H2 (0.37) KMT2ARORCNR1H2NR1H3KLK7
SCHEMBL22903589 0.84 NR1H2 (0.37) KMT2ARORCNR1H2NR1H3KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348516-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-11-02 — — US disclosed
US-11638707-B2 Substituted amino triazoles useful as chitinase inhibitors MOLECURE S.A. (PL) 2023-05-02 — — US disclosed
CN-114174280-A Substituted aminotriazoles useful as chitinase inhibitors 昂科艾伦迪治疗法公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348516-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS CHI3L1, CHI3L2, CHIA KMT2A 2797/4885RORC 3256/4885NR1H2 3917/4885
US-11638707-B2 Substituted amino triazoles useful as chitinase inhibitors CHIT1, CHIA, CHI3L1 KMT2A 2195/4885RORC 1665/4885NR1H2 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback